Abstract
The Raf/MEK/ERK (MAPK) signal transduction cascade is a vital mediator of a number of cellular fates including growth, proliferation and survival, among others. The focus of this review centers on the MAPK signal transduction pathway, its mechanisms of activation, downstream mediators of signaling, and the transcription factors that ultimately alter gene expression. Furthermore, negative regulators of this cascade, including phosphatases, are discussed with an emphasis placed upon chemotherapeutic intervention at various points along the pathway. In addition, mounting evidence suggests that the PI3K/Akt pathway may play a role in the effects elicited via MAPK signaling; as such, potential interactions and their possible cellular ramifications are discussed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias
Leukemia Open Access 13 June 2023
-
HNRNPA2B1 regulates the epithelial–mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway
Cancer Cell International Open Access 10 January 2017
-
Novel cycloartane triterpenoid from Cimicifuga foetida (Sheng ma) induces mitochondrial apoptosis via inhibiting Raf/MEK/ERK pathway and Akt phosphorylation in human breast carcinoma MCF-7 cells
Chinese Medicine Open Access 11 January 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031–1037
Boulton TG, Yancopoulos GD, Gregory JS, Slaughter C, Moomaw C, Hsu J, Cobb MH . An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control Science 1990 249: 64–67
Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Ranayotatos N, Cobb MH, Yancopoulos GD . ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF Cell 1991 65: 663–675
Rossomando AJ, Payne DM, Weber MJ, Sturgill TW . Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase Proc Natl Acad Sci USA 1989 86: 6940–6943
Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW . Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase) EMBO J 1991 10: 885–892
Seger R, Seger D, Lozeman FJ, Ahn NG, Graves LM, Campbell JS, Ericsson L, Harrylock M, Jensen AM, Krebs EG . Human T-cell mitogen-activated protein kinase kinases are related to yeast signal Transduction kinases J Biol Chem 1992 267: 25628–25631
Crews C, Alesandrini A, Erikson R . The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product Science 1992 258: 478–480
Kosako H, Gotoh Y, Matsuda S, Ishikawa M, Nishida E . Xenopus MAP kinase activator is a serine/threonine/tyrosine kinase activated by threonine phosphorylation EMBO J 1992 11: 2903–2908
Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J . Raf-1 activates MAP kinase-kinase Nature 1992 358: 417–421
Dent P, Haser W, Haystead TAJ, Vincent LA, Roberts TM, Sturgill TW . Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro Science 1992 257: 1404–1407
Khleif SN, Abrams SI, Hamilton JM, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra CH, Schlom J . A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors J Immunother 1999 22: 155–165
McCubrey JA, May WS, Duronio V, Mufson A . Serine/Threonine phosphorylation in cytokine signal transduction Leukemia 2000 14: 9–21
New L, Han J . The p38 MAP kinase pathway and its biological function Trends Cardiovasc Med 1998 8: 220–228
Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumary S, Green D, McNulty D, Blummenthal MJ, Heys JR, Landvatter SW, Strickler JE, McLaughlin MM, Siemens IR, Fisher SM, Livi GP, White JR, Adams JL, Young PR . A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 1994 372: 739–746
Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J . Characterization of the structure and function of a new mitogen-activated protein kinase (p38β) J Biol Chem 1996 271: 17920–17926
Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L, Di Padova F, Ulevitch RG, Han J . Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38 J Biol Chem 1997 272: 30122–30128
Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A . ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation Proc Natl Acad Sci USA 1996 93: 4355–4359
Enslen H, Brancho DM, Davis RJ . Molecular determinants that mediate selective activation of p38 MAP kinase isoforms EMBO J 2000 19: 1301–1311
Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J, Kyriakis J, Zon LI . Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun Nature 1994 372: 794–798
Derijard B, Rainegeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ . Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms Science 1995 267: 682–685
Moriguchi T, Toyoshima F, Masuyama N, Hanafusa H, Gotoh Y, Nishida E . A novel SAPK/JNK kinase, MKK7, stimulated by TNFalpha and cellular stresses EMBO J 1997 16: 7045–7053
Ichijo H . From receptors to stres-activated MAP kinases Oncogene 1999 18: 6087–6093
Blalock WL, Weinstein-Oppenheimer CR, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA . Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs Leukemia 1999 14: 1109–1166
Okuda K, Foster R, Griffin J . Signaling domains of the βc chain of the GM-CSF/IL-3/IL-5 receptor Ann NY Acad Sci 1999 872: 305–312
Hackel PO, Zwick E, Prenzel N, Ullrich A . Epidermal growth factor receptors: critical mediators of multiple receptor pathways Curr Opin Cell Biol 1999 11: 184–189
Emaduddin M, Ekman S, Ronnstrand L, Heldin CH . Functional cooperation between the subunits in heterodimeric platelet-derived growth factor receptor complexes Biochem J 1999 341: 523–528
Wells A . EGF Receptor Int J Biochem Cell Biol 1999 31: 637–643
Heldin CH, Westermark B . Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 1999 79: 1283–1316
Khazaie K, Schirrmacher V, Lichtner RB . EGF receptor in neoplasia and metastasis Cancer Metas Rev 1993 12: 255–274
Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK, Lee AV . Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth Cancer Res 2001 15: 5771–5777
Wang JY, Del Valle L, Gordon J, Rubini M, Romano G, Croul S, Peruzzi F, Khalili K, Reiss K . Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas Oncogene 2001 29: 3857–3868
Benini S, Manara MC, Baldini N, Cerisano V, Serra M, Mercuri M, Lollini PL, Nanni P, Picci P, Scotlandi K . Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells Clin Cancer Res 2001 6: 1790–1797
Hoog A, Kjellman M, Nordqvist AC, Hoog CM, Juhlin C, Falkmer S, Schalling M, Grimelius L . Insulin-like growth factor-II in endocrine pancreatic tumours. Immunohistochemical, biochemical and in situ hybridization findings APMIS 2001 109: 127–140
Merchav S . The haematopoietic effects of growth hormone and insulin-like growth factor-I J Pediatr Endocrinol Metab 1998 11: 677–685
Schmiegelow M, Hertz H, Schmiegelow K, Holm K, Muller J . Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children J Pediatr Hematol Oncol 1999 21: 268–273
Arguelles B, Barrios V, Pozo J, Munoz MT, Argente J . Modifications of growth velocity and the insulin-like growth factor system in children with acute lymphoblastic leukemia: a longitudinal study J Clin Endocrinol Metab 2001 85: 4087–4092
Valertinis B, Baserga R . IGF-1 receptor signaling in transformation and differentiation Mol Pathol 2001 54: 133–137
Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R . Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis Mol Cell Biol 1999 19: 7203–7215
Navarro M, Baserga R . Limited redundancy of survival signals from the type I insulin-like growth factor receptor Endocrinology 2001 142: 1073–1081
Kellerer M, Obermaier-Kusser B, Ermel B, Wallner U, Haring HU, Petrides PE . An altered IGF-1 receptor is present in human leukemic cells J Biol Chem 1990 265: 9340–9345
Baier TG, Jenne EW, Blum W, Schonberg D, Hartmann KK . Influence of antibodies against IGF-1, insulin, or their receptors on proliferation of human acute lymphoblastic leukemia cell lines Leuk Res 1992 16: 807–814
Sinclair J, McClain D, Taetle R . Effects of insulin and insulin-like growth factor I on growth of human leukemia cells in serum-free and protein-free medium Blood 1988 71: 66–72
McCubrey JA, Steelman LS, Mayo MW, Algate PA, Dellow RA, Kaleko M . Growth-promoting effects of insulin-like growth factor-1 (IGF-1) on hematopoietic cells: overexpression of introduced IGF-1 receptor abrogates interleukin-3 dependency of murine factor-dependent cells by a ligand-dependent mechanism Blood 1991 78: 921–929
Oliveira MR, Ohnuma L, Bendit I, Dorlhiac-Lacer P, Giannella-Neto D . Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia Leuk Res 2001 25: 711–717
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME . Regulation of neuronal survival by the serine-threonine protein kinase Akt Science 1997 275: 295–299
Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G . Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB Nature 1997 385: 544–548
McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC . Synergistic effects of PI3K/Akt on abrogation of cytokine-dependency induced by oncogenic Raf Adv Enz Reg 2001 41: 289–323
Heldin CH, Westermark B . Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 1999 79: 1283–1316
Li X, Ponten A, Aase K, Karlsson L, Abramsson A, Uutela M, Backstrom G, Hellstrom M, Bostrom H, Li H, Soriano P, Betsholtz C, Heldin CH, Alitalo K, Ostman A, Eriksson U . PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor Nat Cell Biol 2000 2: 302–309
LaRochelle WJ, Jeffers M, McDonald WF, Chillakuru RA, Giese NA, Lokker NA, Sullivan C, Boldog FL, Yang M, Vernet C, Burgess CE, Fernandes E, Deegler LL, Rittman B, Shimkets J, Shimkets RA, Rothberg JM, Lichenstein HS . PDGF-D, a new protease-activated growth factor Nat Cell Biol 2001 3: 517–521
Jones SM, Klinghoffer R, Prestwich GD, Toker A, Kazlauskas A . PDGF induces an early and a late wave of PI 3-kinase activity, and only the late wave is required for progression through G1 Curr Biol 1999 9: 512–521
Bos JL . Ras-like GTPases Biochim Biophys Acta 1997 1333: M19–M31
Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG . The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways Proc Natl Acad Sci USA 1996 93: 14845–14850
Golub TR, Barker GF, Lovett M, Gilliland DG . Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation Cell 1994 77: 307–316
Sjoblom T, Boureux A, Ronnstrand L, Heldin CH, Ghysdael J, Ostman A . Characterization of the chronic myelomonocytic leukemia associated TEL-PDGF beta R fusion protein Oncogene 1999 18: 7055–7062
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, Berthou C, Lessard M, Berger R, Ghysdael J, Bernard OA . A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia Science 1997 278: 1309–1312
Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y . Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis Br J Haematol 1994 86: 303–307
Tsai LH, White L, Raines E, Ross R, Smith RG, Cushley W, Ozanne B . Expression of platelet-derived growth factor and its receptors by two pre-B acute lymphocytic leukemia cell lines Blood 1994 83: 51–55
Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R . Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF Science 1991 253: 1129–1132
Rutherford C, Martin W, Salame M, Carrier M, Anggard E, Ferns G . Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor Atherosclerosis 1997 130: 45–51
Vassbotn FS, Langeland N, Hagen I, Holmsen H . A monoclonal antibody against PDGF B-chain inhibits PDGF-induced DNA synthesis in C3H fibroblasts and prevents binding of PDGF to its receptor Biochim Biophys Acta 1990 1054: 246–249
Koyama H, Nishizawa Y, Hosoi M, Fukumoto S, Kogawa K, Shioi A, Morii H . The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by platelet-derived growth factor and insulin-like growth factor-I. Possible involvement of cyclin-dependent kinase 2 Circ Res 1996 79: 757–764
LaRochelle WJ, Jensen RA, Heidaran MA, May-Siroff M, Wang LM, Aaronson SA, Pierce JH . Inhibition of platelet-derived growth factor autocrine growth stimulation by a monoclonal antibody to the human alpha platelet-derived growth factor receptor Cell Growth Diff 1993 4: 547–553
Lokker NA, O'Hare JP, Barsoumian A, Tomlinson JE, Ramakrishnan V, Fretto LJ, Giese NA . Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies J Biol Chem 1997 272: 33037–33044
Drolet DW, Jenison RD, Smith DE, Pratt D, Hicke BJ . A high throughput platform for systematic evolution of ligands by exponential enrichment (SELEX) Comb Chem High Throughput Screen 1999 2: 271–278
Duan DS, Pazin MJ, Fretto LJ, Williams LT . A functional soluble extracellular region of the platelet-derived growth factor (PDGF) beta-receptor antagonizes PDGF-stimulated responses J Biol Chem 1991 266: 413–418
Schroeder MC, Hamby JM, Connolly CJ, Grohar PJ, Winters RT, Barvian MR, Moore CW, Boushelle SL, Crean SM, Kraker AJ, Driscoll DL, Vincent PW, Elliott WL, Lu GH, Batley BL, Dahring TK, Major TC, Panek RL, Doherty AM, Showalter HD . Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure–activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity J Med Chem 2001 44: 1915–1926
Palmer BD, Kraker AJ, Hartl BG, Panopoulos AD, Panek RL, Batley BL, Lu GH, Trumpp-Kallmeyer S, Hollis Showalter HD, Denny WA . Structure–activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor J Med Chem 1999 42: 2373–2382
Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA . In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor J Pharmacol Exp Ther 1997 283: 1433–1444
Omura T, Miyazawa K, Ostman A, Heldin CH . Identification of a 190-kDa vascular endothelial growth factor 165 cell surface binding protein on a human glioma cell line J Biol Chem 1997 272: 12676–12682
Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A . Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation Cancer Res 1994 54: 6106–6114
Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, Bohmer FD . Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296 Biochemistry 1997 36: 6260–6269
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB . Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class Proc Natl Acad Sci USA 1995 92: 2558–2562
Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100–104
Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmerman J, Lydon NB, Gilliland DG, Druker BJ . CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 1997 90: 4947–4952
Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ . Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide Clin Cancer Res 1997 3: 1167–1177
Yagi M, Kato S, Kobayashi Y, Kobayashi N, Iinuma N, Nakamura K, Kubo K, Ohyama SI, Murooka H, Shimizu T, Nishitoba T, Osawa T, Nagano N . Beneficial effects of a novel inhibitor of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis Gen Pharmacol 1998 31: 765–773
Bilder G, Wentz T, Leadley R, Amin D, Byan L, O'Conner B, Needle S, Galczenski H, Bostwick J, Kasiewski C, Myers M, Spada A, Merkel L, Ly C, Persons P, Page K, Perrone M, Dunwiddie C . Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A Circulation 1999 99: 3292–3299
Mauro MJ, Druker BJ . STI571: targeting BCR-ABL as therapy for CML Oncologist 2001 6: 230–232
Mauro MJ, Druker BJ . STI571: a gene product-targeted therapy for leukemia Curr Oncol Rep 2001 3: 223–227
Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F . PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration Cancer Res 2000 60: 2178–2189
Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H . Platelet-derived growth factor receptor tyrosine kinase inhibitor AG1295 attenuates rat hepatic stellate cell growth J Lab Clin Med 2001 135: 406–412
Shoelson SE, Sivaraja M, Williams KP, Hu P, Schlessinger J, Weiss MA . Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation EMBO J 1993 12: 795–802
Wang XY, McCubrey JA . Malignant transformation induced by cytokine genes: a comparison of the abilities of germline and mutated interleukin 3 genes to transform hematopoietic cells by transcriptional and posttranscriptional mechanisms Cell Growth Diff 1996 7: 487–500
Wang XY, McCubrey JA . Regulation of interleukin 3 expression in normal and autocrine transformed hematopoietic cells Intl J Oncol 1997 10: 989–1001
Wang XY, McCubrey JA . Differential effects of retroviral, long terminal repeats on interleukin-3 gene expression and autocrine transformation Leukemia 1997 11: 1711–1725
Wang XY, Hoyle PE, McCubrey JA . Characterization of proteins binding the 3′ regulatory region of the IL-3 gene in IL-3 dependent and autocrine-transformed hematopoietic cells Leukemia 1998 12: 520–531
Steelman LS, Algate PA, Blalock WL, Wang XY, Prevost KD, Hoyle PE, McCubrey JA . Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells Leukemia 1996 10: 528–542
Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells Leukemia 2001 14: 1777–1784
McCormack MP, Gonda TJ . Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common beta subunit Oncogene 1999 18: 7190–7199
D'Andrea RJ, Harrison-Findik D, Butcher CM, Finnie J, Blumbergs P, Bartley P, McCormack M, Jones K, Rowland R, Gonda TJ, Vadas MA . Dysregulated hematopoiesis and a progressive neurological disorder induced by expression of an activated form of the human common beta chain in transgenic mice J Clin Invest 1998 102: 1951–1960
Hoyle PE, Steelman LS, McCubrey JA . Autocrine transformation of human hematopoietic cells after transfection with an activated GM-CSF gene Cytokines Cell Mol Ther 1997 3: 159–168
Gale RE, Freeburn RW, Khwaja A, Chopra R, Linch DC . A truncated isoform of the human beta chain common to the receptors for granulocyte–macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 with increased mRNA expression in some patients with acute leukemia Blood 1998 91: 54–63
Sun Q, Woodcock JM, Rapoport A, Stomski FC, Korpelainen EI, Bagley CJ, Goodall GJ, Smith WB, Gamble JR, Vadas MA, Lopez AF . Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist Blood 1996 87: 83–92
Sun Q, Jones K, McClure B, Cambareri B, Zacharakis B, Iversen PO, Stomski F, Woodcock JM, Bagley CJ, D'Andrea R, Lopez AF . Simultaneous antagonism of interleukin-5, granulocyte–macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors Blood 1999 94: 1943–1951
Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE . Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin granulocyte–macrophage colony-stimulating factor fusion protein Blood 1998 92: 589–595
Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C . Diphtheria toxin fused to granulocyte–macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia Blood 1998 92: 4279–4286
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE . Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias Leukemia 2000 14: 576–585
Kiser M, McCubrey JA, Steelman LS, Shelton JG, Miller MS, Ramage J, Alexander RL, Kucera GL, Pettenati M, Willingham MC, Frankel AE . Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice Leukemia 2001 15: 814–818
Vallera DA, Seo SY, Panoskaltsis-Mortari A, Griffin JD, Blazar BR . Targeting myeloid leukemia with a DT(390)-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice Protein Eng 1999 12: 779–785
McWherter CA, Feng Y, Zurfluh LL, Klein BK, Baganoff MP, Polazzi JO, Hood WF, Paik K, Abegg AL, Grabbe ES, Shieh JJ, Donnelly AM, McKearn JP . Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin Biochemistry 1999 38: 4564–4571
McCubrey JA, Blalock WL, Saleh O, Pearce M, Burrows C, Steelman LS, Lee JT, Franklin RA, Oberhaus SM, Moye PW, Doshi PD, McKearn JP . Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells Leukemia 2001 15: 1203–1216
Abegg AL, Vickery LE, Bremer ME, Donnelly AM, Doshi PD, Evans ML, Thurman TL, Braford SR, Caparon MH, Bauer SC, Giri JG, Welply JK, McKearn JP, Smith WG . The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist Leukemia 2001 (in press)
Srinivasa SP, Doshi PD . Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line Leukemia 2001 16: 244–253
Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T, Ridge S, Carter G, White D, Oscier D, Chevret S, West R . RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up Leukemia 1998 12: 887–892
MacKenzie KL, Dolnikov A, Millington M, Shounan Y, Symonds G . Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice Blood 1999 93: 2043–2056
Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U, Mohr B, Ehninger G, Neubauer A . Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia Br J Haematol 2001 112: 300–307
Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP . FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 2001 97: 3589–3595
Buday L, Downward J . Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor Cell 1993 73: 611–620
Moodie SA, Willumsen BM, Weber MJ, Wolfman A . Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase kinase Science 1993 260: 1658–1660
Vojtek AB, Hollenberg SM, Cooper JA . Mammalian Ras interacts directly with the serine/threonine kinase Raf Cell 1993 74: 205–214
Zhang X, Settleman J, Kyriakis JM, Takeuchi-Suzuki E, Elledge SJ, Marshall MS, Bruder JT, Rapp UR, Avruch J . Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 Nature 1993 364: 308–314
Warne PH, Viciana RP, Downward J . Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro Nature 1993 364: 353–355
Ross EM, Wilkie TM . GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins Annu Rev Biochem 2000 69: 795–827
Adjei AA . Blocking oncogenic Ras signaling for cancer therapy J Natl Cancer Inst 2001 93: 1062–1074
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J . Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical–laboratory correlative trial Blood 2001 97: 3361–3369
Karp JE . Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies Semin Hematol 2001 38: 16–23
Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH . A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity Cancer Res 2000 60: 1871–1877
Du W, Prendergast GC . Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors Cancer Res 1999 59: 5492–5496
Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ . The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis Mol Cell Bio 2000 20: 139–148
Law BK, Norgaard P, Gnudi L, Kahn BB, Poulson HS, Moses HL . Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway J Biol Chem 1999 274: 4743–4748
Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA . Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype Hum Gene Ther 1993 4: 451–460
Song JJ, Lee H, Kim E, Kim YS, Yoo NC, Roh JK, Kim BS, Kim J . Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells Cancer Lett 2000 157: 1–7
Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA . Specific inhibition of K-ras expression and tumorgenicity of lung cancer by antisense RNA Cancer Res 1991 51: 1744–1748
Hagemann C, Rapp UR . Isotype-specific functions of Raf kinases Exp Cell Res 1999 253: 34–46
Franklin RA, McCubrey JA . Kinases: positive and negative regulators of apoptosis Leukemia 2000 14: 2019–2034
White MK, McCubrey JA . Suppression of apoptosis: role in cell growth and neoplasia Leukemia 2001 15: 1011–1021
Eychene A, Dusanter-Fourt I, Barnier JV, Papin C, Charon M, Gisselbrecht S, Calothy G . Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines Oncogene 1995 10: 1159–1165
McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M . Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells Leukemia 1998 12: 1903–1929
McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pearce M, White MK, Franklin RA, Blalock WL . Effects of deregulated Raf and MEK1 expression on the cytokine-dependency of hematopoietic cells Adv Enzyme Regl 2000 40: 305–337
Weinstein-Oppenheimer C, Steelman LS, Algate PA, Blalock WL, Burrows C, Hoyle PE, Lee JT, Moye PW, Shelton JG, Franklin RA, McCubrey JA . Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells Leukemia 2000 14: 1921–1938
Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein-Oppenheimer C, Pearce M, Steelman LS, McMahon M, McCubrey JA . Synergy between Raf and BCL2 in abrogating the cytokine-dependency of hematopoietic cells Leukemia 2000 14: 1060–1079
Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA . Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-dependent tumors Pharm Ther 2000 88: 229–279
Chung GT, Huang DP, Lo KW, Chan MK, Wong FW . Genetic lesion in the carcinogenesis of cervical cancer Anticancer Res 1992 12: 1485–1490
Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, Takahashi R, Sugiyama T, Yoshida O . Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification J Natl Cancer Inst 1994 86: 1331–1335
Ishikawa F, Takaku F, Nagao M, Sugimura T . Rat c-raf oncogene activation by a rearrangement that produces a fused protein Mol Cell Biol 1987 7: 1226–1232
Sithanandam G, Dean M, Brennscheidt U, Beck T, Gazdar A, Minna JD, Brauch H, Zbar B, Rapp UR . Loss of heterozygosity at the c-raf locus in small cell lung carcinoma Oncogene 1989 4: 451–455
Storm SM, Rapp UR . Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors Toxicol Lett 1993 67: 201–210
Weber CK, Slupsky JR, Kalmes HA, Rapp UR . Active Ras induces heterodimerization of cRaf and BRaf Cancer Res 2001 61: 3595–3598
Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M . Complex formation between RAS and RAF and other protein kinases Proc Natl Acad Sci USA 1993 90: 6213–6217
Vojtek AB, Hollenberg SM, Cooper JA . Mammalian Ras interacts directly with the serine/threonine kinase Raf Cell 1993 74: 205–214
Erpel T, Courtneidge SA . Src family protein tyrosine kinases and cellular signal transduction pathways Curr Opin Cell Biol 1995 7: 176–182
Pathan NI, Ashendel CL, Geahlen RL, Harrison ML . Activation of T cell Raf-1 at mitosis requires the protein-tyrosine kinase Lck J Biol Chem 1996 271: 30315–30317
Sozeri O, Vollmer K, Liyanage M, Frith D, Kour G, Mark GE 3rd, Stabel S . Activation of the c-Raf protein kinase by protein kinase C phosphorylation Oncogene 1992 7: 2259–2262
Morrison DK, Heidecker G, Rapp UR, Copeland TD . Identification of the major phosphorylation sites of the Raf-1 kinase J Biol Chem 1993 268: 17309–17316
Farrar MA, Alberol-Ila J, Perlmutter RM . Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization Nature 1996 383: 178–181
Weber CK, Slupsky JR, Herrmann C, Schuler M, Rapp UR, Block C . Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes Oncogene 2000 19: 169–176
Chang F, McCubrey JA . p21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells Oncogene 2001 20: 4353–4364
Schulte TW, Blagosklonny MV, Ingui C, Neckers L . Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association J Biol Chem 1995 270: 24585–24588
Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM . Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway Mol Cell Biol 1996 16: 5839–5845
Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y, Neckers LM . The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy Leukemia 2001 15: 1537–1543
Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S . KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules Cancer Res 1999 59: 2931–2938
Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S . Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex Blood 2000 96: 2284–2291
Kimoto M, Sakamoto K, Shirouzu M, Hirao I, Yokoyama S . RNA aptamers that specifically bind to the Ras-binding domain of Raf-1 FEBS Lett 1998 441: 322–326
Barnard D, Sun H, Baker L, Marshall MS . In vitro inhibition of Ras-Raf association by short peptides Biochem Biophys Res Commun 1998 247: 176–180
Cioffi CL, Garay M, Johnston JF, McGraw K, Boggs RT, Hreniuk D, Monia BP . Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation Mol Pharmacol 1997 51: 383–389
Schumacher C, Cioffi CL, Sharif H, Haston W, Monia BP, Wennogle L . Exposure of human vascular smooth muscle cells to Raf-1 antisense oligodeoxynucleotides: cellular responses and pharmacodynamic implications Mol Pharmacol 1998 53: 97–104
Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR . Protein kinase C alpha activates RAF-1 by direct phosphorylation Nature 1993 364: 249–252
Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB . PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase Oncogene 1996 13: 2517–2526
Zhang Y, Yao B, Delikat S, Bayoumy S, Lin XH, Basu S, McGinley M, Chan-Hui PY, Lichenstein H, Kolesnick R . Kinase suppressor of Ras is ceramide-activated protein kinase Cell 1997 89: 63–72
Xia K, Mukhopadhyay NK, Inhorn RC, Barber DL, Rose PE, Lee RS, Narsimhan RP, D'Andrea AD, Griffin JD, Roberts TM . The cytokine-activated tyrosine kinase JAK2 activates Raf-1 in a p21ras-dependent manner Proc Natl Acad Sci USA 1996 93: 11681–11686
Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ . Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases J Biol Chem 1997 272: 4378–4383
Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R . Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation EMBO J 1999 18: 2137–2148
Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell JE Jr . Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions Cell 1994 76: 821–828
Darnell JE Jr, Kerr IM, Stark GR . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 1994 264: 1415–1421
Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O . Signaling by the cytokine receptor superfamily: JAKs and STATs Trends Biochem Sci 1994 19: 222–227
Goodman PA, Niehoff LB, Uckun FM . Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells J Biol Chem 1998 273: 17742–17748
Sudbeck EA, Liu XP, Narla RK, Mahajan S, Ghosh S, Mao C, Uckun FM . Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents Clin Cancer Res 1999 5: 1569–1582
Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM . Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor Nature 1996 379: 645–648
Eriksen KW, Kaltoft K, Mikkelsen G, Nielsen M, Zhang Q, Geisler C, Nissen MH, Ropke C, Wasik MA, Odum N . Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells Leukemia 2001 15: 787–793
De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B . JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells Br J Haematol 2000 109: 823–828
Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR . Protein kinase C alpha activates RAF-1 by direct phosphorylation Nature 1993 364: 249–252
Tamaoki T . Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors Meth Enzymol 1991 201: 340–347
Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H . UCN-01, a selective inhibitor of protein kinase C from Streptomyces J Antibiot 1987 40: 1782–1784
Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ . Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue Mol Pharmacol 1994 45: 1207–1214
Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ . Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells Cancer Res 1993 53: 2081–2086
Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA . Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2 Cell Growth Differ 1995 6: 927–936
Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G, Matter A . A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative, as well as in vivo anti-tumor activity Int J Cancer 1989 43: 851–856
Thavasu P, Propper D, McDonald A, Dobbs N, Ganesan T, Talbot D, Braybrook J, Caponigro F, Hutchison C, Twelves C, Man A, Fabbro D, Harris A, Balkwill F . The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients Cancer Res 1999 59: 3980–3984
Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T . Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent Pharmacol Ther 1999 82: 293–301
Morrison DK . KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 2001 114: 1609–1612
Zhang Y, Yao B, Delikat S, Bayoumy S, Lin XH, Basu S, McGinley M, Chan-Hui PY, Lichenstein H, Kolesnick R . Kinase suppressor of Ras is ceramide-activated protein kinase Cell 1997 89: 63–72
Denouel-Galy A, Douville EM, Warne PH, Papin C, Laugier D, Calothy G, Downward J, Eychene A . Murine Ksr interacts with MEK and inhibits Ras-induced transformation Cell Biol 1998 8: 46–55
Jacobs D, Glossip D, Xing H, Muslin AJ, Kornfeld K . Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase Genes Dev 2001 13: 163–175
Muller J, Cacace AM, Lyons WE, McGill CB, Morrison DK . Identification of B-KSR1, a novel brain-specific isoform of KSR1 that functions in neuronal signaling Mol Cell Biol 2000 20: 5529–5539
Cacace AM, Michaud NR, Therrien M, Mathes K, Copeland T, Rubin GM, Morrison DK . Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14–3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression Mol Cell Biol 1999 19: 229–240
Therrien M, Michaud NR, Rubin GM, Morrison DK . KSR modulates signal propagation within the MAPK cascade Genes Dev 1996 10: 2684–2695
Zheng CF, Guan KL . Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases J Biol Chem 1993 268: 23933–23939
English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH . Isolation of MEK5 and differential expression of alternatively spliced forms J Biol Chem 1995 270: 28897–28902
Catling AD, Schaeffer HJ, Reuter CW, Reddy GR, Weber MJ . A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function Mol Cell Biol 1995 15: 5214–5225
Zheng CF, Guan KL . Activation of MEK family kinases requires phosphorylation of two conserved Ser/Thr residues EMBO J 1994 13: 1123–1131
Papin C, Eychene A, Brunet A, Pages G, Pouyssegur J, Calothy G, Barnier JV . B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222 Oncogene 1995 10: 1647–1651
Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr Rev 2001 22: 153–183
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG . Transformation of mammalian cells by constitutively active MAP kinase kinase Science 1994 265: 966–970
Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD . Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1 Exp Hematol 1994 11: 1111–1117
Kang CD, Yoo SD, Hwang BW, Kim KW, Kim DW, Kim CM, Kim SH, Chung BS . The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells Leuk Res 2000 24: 527–534
Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA . A conditionally active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells Oncogene 2000 19: 526–536
Blalock WL, Moye PW, Chang F, Pearch M, Steelman LS, McMahon M, McCubrey JA . Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine-dependency of hematopoietic cells Adv Enzyme Regl 2000 40: 305–337
Blalock WL, Pearce M, Chang F, Lee JT, Pohnert S, Burrows C, Steelman LS, Franklin RA, McMahon M, McCubrey JA . Effects of inducible MEK1 activation on the cytokine-dependency of lymphoid cells Leukemia 2001 15: 794–807
Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M, McCubrey JA . Differential abilities of the Raf family of protein kinases to abrogate cytokine-dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism Leukemia 2000 14: 642–656
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR . PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo J Biol Chem 1995 270: 27489–27494
Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR . A synthetic inhibitor of the mitogen-activated protein kinase cascade Proc Natl Acad Sci USA 1995 92: 7686–7689
Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S, Pouyssegur J . Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation Proc Natl Acad Sci USA 1993 90: 8319–8323
Eliceiri BP, Klemke R, Stromblad S, Cheresh DA . Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis J Cell Biol 1998 140: 1255–1263
Pang L, Sawada T, Decker SJ, Saltiel AR . Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor J Biol Chem 1995 270: 13585–13588
Finlay D, Healy V, Furlong F, O'Connell FC, Keon NK, Martin F . MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival Cell Death Differ 2000 7: 302–313
Holmstrom TH, Tran SE, Johnson VL, Ahn NG, Chow SC, Eriksson JE . Inhibition of mitogen-activated kinase signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis Mol Cell Biol 1999 19: 5991–6002
Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM . Identification of a novel inhibitor of mitogen-activated protein kinase kinase J Biol Chem 1998 273: 18623–18632
Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR . Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 1999 5: 810–816
Sebolt-Leopold JS . Development of anticancer drugs targeting the MAP kinase pathway Oncogene 2000 19: 6594–6599
Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, Grant S . Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells Cancer Res 2001 61: 5106–5115
Deb A, Zamanian-Daryoush M, Xu Z, Kadereit S, Williams RG . Protein kinase PKR is required for platelet-derived growth factor signaling of c-fos gene expression via Erks and Stat3 EMBO J 2001 20: 2487–2496
Peus D, Vasa RA, Beyerle A, Meves A, Krautmacher C, Pittelkow MR . UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes J Invest Derm 1999 112: 751–756
Bhat NR, Zhang P . Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death J Neurochem 1999 72: 112–119
Stevenson MA, Pollock SS, Coleman CN, Calderwood SK . X-irradiation, phorbol esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates Cancer Res 1994 54: 12–15
Ferrell JE Jr . MAP kinases in mitogenesis and development Curr Top Dev Biol 1996 33: 1–60
Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH . Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation Cell 1998 93: 605–615
Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ . Activation mechanism of the MAP kinase ERK2 by dual phosphorylation Cell 1997 90: 859–869
Cobb MH, Goldsmith EJ . Dimerization in MAP-kinase signaling Trends Biochem Sci 2000 25: 7–9
Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M, Osheroff N, Ahn NG . Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation Mol Cell Biol 1999 19: 3551–3560
Sturgill TW, Ray LB, Erikson E, Maller JL . Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II Nature 1988 334: 715–718
Seger R, Krebs EG . The MAPK signaling cascade FASEB J 1995 9: 726–735
Poteet-Smith CE, Smith JA, Lannigan DA, Freed TA, Sturgill TW . Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family J Biol Chem 1999 274: 22135–22138
Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW, Lee WJ . Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1 Blood 1999 93: 3893–3899
Morgan MA, Dolp O, Reuter CW . Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling Blood 2001 97: 1823–1834
Ajenjo N, Aaronson DS, Ceballos E, Richard C, Leon J, Crespo P . Myeloid leukemia cell growth and differentiation are independent of mitogen-activated protein kinase ERK1/2 activation J Biol Chem 2000 275: 7189–7197
Iida M, Towatari M, Nakao A, Iida H, Kiyoi H, Nakano Y, Tanimoto M, Saito H, Naoe T . Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation Leukemia 1999 13: 585–589
Horiuchi KY, Scherle PA, Trzaskos JM, Copeland RA . Competitive inhibition of MAP kinase activation by a peptide representing the alpha C helix of ERK Biochemistry 1998 37: 8879–8885
Zhang H, Shi X, Hampong M, Blanis L, Pelech S . Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase J Biol Chem 2001 276: 6905–6908
Fisher TL, Blenis J . Evidence for two catalytically active kinase domains in pp90rsk Mol Cell Biol 1996 16: 1212–1219
Alcorta DA, Crews CM, Sweet LJ, Bankston L, Jones SW, Erikson RL . Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase Mol Cell Biol 1989 9: 3850–3859
Moller DE, Xia CH, Tang W, Zhu AX, Jakubowski M . Human rsk isoforms: cloning and characterization of tissue-specific expression Am J Physiol 1994 266: C351–C359
Zhao Y, Bjorbaek C, Weremowicz S, Morton CC, Moller DE . RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation Mol Cell Biol 1995 15: 4353–4363
Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frodin M . 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1 J Biol Chem 1999 274: 27168–27176
Frodin M, Jensen CJ, Merienne K, Gammeltoft S . A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1 EMBO J 2000 19: 2924–2934
Xing J, Ginty DD, Greenberg ME . Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase Science 1996 273: 959–963
Joel PB, Smith J, Sturgill TW, Fisher TL, Blenis J, Lannigan DA . pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167 Mol Cell Biol 1998 18: 1978–1984
Schouten GJ, Vertegaal AC, Whiteside ST, Israel A, Toebes M, Dorsman JC, van der Eb AJ, Zantema A . IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase EMBO J 1997 16: 3133–3144
Ghoda L, Lin X, Greene WC . The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro J Biol Chem 1997 272: 21281–21288
Chen RH, Abate C, Blenis J . Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase Proc Natl Acad Sci USA 1993 90: 10952–10956
Crans HN . Transcription factors and translocations in lymphoid and myeloid leukemia Leukemia 2001 15: 313–331
Jean D, Harbison M, McConkey DJ, Ronai Z, Bar-Eli M . CREB and its associated proteins act as survival factors for human melanoma cells J Biol Chem 1998 273: 24884–24890
Ginty DD, Bonni A, Greenberg ME . Nerve growth factor activates a Ras-dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB Cell 1994 77: 713–725
Sakamoto KM, Fraser JK, Lee HJ, Lehman E, Gasson JC . Granulocyte–macrophage colony-stimulating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter Mol Cell Biol 1994 14: 5975–5985
Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM, Reusch JE . Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein J Biol Chem 1999 274: 27529–27535
Facchini LM, Penn LZ . The molecular role of Myc in growth and transformation: recent discoveries lead to new insights FASEB J 1998 12: 633–651
Boyd KE, Farnham PJ . Identification of target genes of oncogenic transcription factors Proc Soc Exp Biol Med 1999 222: 9–28
Li LH, Nerlov C, Prendergast G, MacGregor D, Ziff EB . c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II EMBO J 1994 13: 4070–4079
Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M . Repression of cyclin D1: a novel function of MYC Mol Cell Biol 1994 14: 4032–4043
Reisman D, Elkind NB, Roy B, Beamon J, Rotter V . c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif Cell Growth Differ 1993 4: 57–65
Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L, Schmidt EV . An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc Mol Cell Biol 1996 16: 4754–4764
Bello-Fernandez C, Packham G, Cleveland JL . The ornithine decarboxylase gene is a transcriptional target of c-Myc Proc Natl Acad Sci USA 1993 90: 7804–7808
Dittmer J, Nordheim A . Ets transcription factors and human disease Biochim Biophys Acta 1998 1377: F1–F11
Iwasaka C, Tanaka K, Abe M, Sato Y . Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells J Cell Physiol 1996 169: 522–531
Schneikert J, Peterziel H, Defossez PA, Klocker H, Launoit Y, Cato AC . Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression J Biol Chem 1996 271: 23907–23913
Gambarotta G, Boccaccio C, Giordano S, Ando M, Stella MC, Comoglio PM . Ets up-regulates MET transcription Oncogene 1996 13: 1911–1917
Dittmer J, Gitlin SD, Reid RL, Brady JN . Transactivation of the P2 promoter of parathyroid hormone-related protein by human T-cell lymphotropic virus type I Tax1: evidence for the involvement of transcription factor Ets1 J Virol 1993 67: 6087–6095
Shaulian E, Karin M . AP-1 in cell proliferation and survival Oncogene 2001 20: 2390–2400
Lee W, Haslinger A, Karin M, Tjian R . Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40 Nature 1987 325: 368–372
Fu Sl, Bottoli I, Goller M, Vogt PK . Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation Proc Natl Acad Sci USA 1999 96: 5716–5721
Cohen SB, Waha A, Gelman IH, Vogt PK . Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine fibroblasts Oncogene 2001 20: 141–146
Vial E, Perez S, Castellazzi M . Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors Oncogene 2000 19: 5020–5029
Epinat JC, Gilmore TD . Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway Oncogene 1999 18: 6896–6909
Chen FE, Ghosh G . Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views Oncogene 1999 18: 6845–6852
Chen C, Edelstein LC, Gelinas C . The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L) Mol Cell Biol 2000 20: 2687–2695
Schreck R, Baeuerle PA . NF-kappa B as inducible transcriptional activator of the granulocyte–macrophage colony-stimulating factor gene Mol Cell Biol 1990 10: 1281–1286
Duyao MP, Kessler DJ, Spicer DB, Sonenshein GE . Transactivation of the c-myc gene by HTLV-1 tax is mediated by NFkB Curr Top Microbiol Immunol 1992 182: 421–424
Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr . NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1 Mol Cell Biol 1999 19: 5785–5799
Xing J, Ginty DD, Greenberg ME . Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase Science 1996 273: 959–963
Xing J, Kornhauser JM, Xia Z, Thiele EA, Greenberg ME . Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation Mol Cell Biol 1998 18: 1946–1955
Parker D, Ferreri K, Nakajima T, LaMorte VJ, Evans R, Koerber SC, Hoeger C, Montminy MR . Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism Mol Cell Biol 1996 16: 694–703
Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH . Phosphorylated CREB binds specifically to the nuclear protein CBP Nature 1993 365: 855–859
Wagner EF . AP-1: Introductory remarks Oncogene 2001 20: 2334–2335
Yu W, Fantl WJ, Harrowe G, Williams LT . Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK Curr Biol 1998 8: 56–64
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M . Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 Nature 1991 354: 494–496
Hibi M, Lin A, Smeal T, Minden A, Karin M . Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain Genes Dev 1993 7: 2135–2148
Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ . JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain Cell 1994 76: 1025–1037
Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R, Karin M . c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases Mol Cell Biol 1994 14: 6683–6688
Chou SY, Baichwal V, Ferrell JE Jr . Inhibition of c-Jun DNA binding by mitogen-activated protein kinase Mol Biol Cell 1992 3: 1117–1130
Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M . Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 Nature 1991 354: 494–496
Binetruy B, Smeal T, Karin M . Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain Nature 1991 351: 122–127
Lloyd A, Yancheva N, Wasylyk B . Transformation suppressor activity of a Jun transcription factor lacking its activation domain Nature 1991 352: 635–638
Johnson R, Spiegelman B, Hanahan D, Wisdom R . Cellular transformation and malignancy induced by ras require c-jun Mol Cell Biol 1996 16: 4504–4511
Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y, Sonobe MH, Kameda T, Ichinose M, Miki K, Iba H . Analysis of AP-1 function in cellular transformation pathways J Virol 1994 68: 3527–3535
Chen RH, Abate C, Blenis J . Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase Proc Natl Acad Sci USA 1993 90: 10952–10956
Chen RH, Juo PC, Curran T, Blenis J . Phosphorylation of c-Fos at the C-terminus enhances its transforming activity Oncogene 1996 12: 1493–1502
Davis RJ . Signal transduction by the c-Jun N-terminal kinase Biochem Soc Symp 1999 64: 1–12
van Dam H, Castellazzi M . Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis Oncogene 2001 20: 2453–2464
Chiariello M, Marinissen MJ, Gutkind JS . Multiple mitogen-activated protein kinase signaling pathways connect the cot oncoprotein to the c-jun promoter and to cellular transformation Mol Cell Biol 2000 20: 1747–1758
Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S . Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation Genes Dev 1995 9: 2723–2735
Pahl HL . Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 1999 18: 6853–6866
Lee FS, Hagler J, Chen ZJ, Maniatis T . Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway Cell 1997 88: 213–222
Baeuerle PA, Baltimore D . NF-kappa B: ten years after Cell 1996 87: 13–20
Li S, Sedivy JM . Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex Proc Natl Acad Sci USA 1993 90: 9247–9251
Ghoda L, Lin X, Greene WC . The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro J Biol Chem 1997 272: 21281–21288
Schouten GJ, Vertegaal AC, Whiteside ST, Israel A, Toebes M, Dorsman JC, van der Eb AJ, Zantema A . IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase EMBO J 1997 16: 3133–3144
Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ . The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clin Cancer Res 1999 5: 119–127
Giallongo A, Appella E, Ricciardi R, Rovera G, Croce CM . Identification of the c-myc oncogene product in normal and malignant B cells Science 1983 222: 430–432
Ramsay G, Evan GI, Bishop JM . The protein encoded by the human proto-oncogene c-myc Proc Natl Acad Sci USA 1984 81: 7742–7746
Schmidt EV . The role of c-myc in cellular growth control Oncogene 1999 18: 2988–2996
Grandori C, Cowley SM, James LP, Eisenman RN . The Myc/Max/Mad network and the transcriptional control of cell behavior Annu Rev Cell Dev Biol 2000 16: 653–699
Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE . Inhibition of cell proliferation by the Mad1 transcriptional repressor Mol Cell Biol 1996 16: 2796–2801
Baudino TA, Cleveland JL . The Max network gone mad Mol Cell Biol 2001 21: 691–702
Fujioka Y, Taira T, Maeda Y, Tanaka S, Nishihara H, Iguchi-Ariga SM, Nagashima K, Ariga H . MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer J Biol Chem 2001 276: 45137–45144
Mori K, Maeda Y, Kitaura H, Taira T, Iguchi-Ariga SM, Ariga H . MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc J Biol Chem 1998 273: 29794–29800
Seth A, Alvarez E, Gupta S, Davis RJ . A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression J Biol Chem 1991 266: 23521–23524
Seth A, Gonzalez FA, Gupta S, Raden DL, Davis RJ . Signal transduction within the nucleus by mitogen-activated protein kinase J Biol Chem 1992 267: 24796–24804
Lutterbach B, Hann SR . c-Myc transactivation domain-associated kinases: questionable role for map kinases in c-Myc phosphorylation J Cell Biochem 1999 72: 483–491
Colman MS, Ostrowski MC . The transactivation potential of a c-Myc N-terminal region (residues 92–143) is regulated by growth factor/Ras signaling Nucleic Acids Res 1996 24: 1971–1978
Sears R, Leone G, DeGregori J, Nevins JR . Ras enhances Myc protein stability Mol Cell 1999 3: 169–179
Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR . Regulation of c-myc expression by Ras/Raf signalling Oncogene 1998 16: 211–216
Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y . Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase J Biol Chem 1999 274: 32580–32587
Wasylyk B, Hagman J, Gutierrez-Hartmann A . Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway Trends Biochem Sci 1998 23: 213–216
Wasylyk B, Hahn SL, Giovane A . The Ets family of transcription factors Eur J Biochem 1993 211: 7–18
Sementchenko VI, Watson DK . Ets target genes: past, present and future Oncogene 2000 19: 6533–6548
Yordy JS, Muise-Helmericks RC . Signal transduction and the Ets family of transcription factors Oncogene 2000 19: 6503–6513
Brunner D, Ducker K, Oellers N, Hafen E, Scholz H, Klambt C . The ETS domain protein pointed-P2 is a target of MAP kinase in the sevenless signal transduction pathway Nature 1994 370: 386–389
Hipskind RA, Buscher D, Nordheim A, Baccarini M . Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors Genes Dev 1994 8: 1803–1816
Hipskind RA, Baccarini M, Nordheim A . Transient activation of RAF-1, MEK, and ERK2 coincides kinetically with ternary complex factor phosphorylation and immediate-early gene promoter activity in vivo Mol Cell Biol 1994 14: 6219–6231
Keyse SM . Protein phosphatases and the regulation of mitogen-activated protein kinase signalling Curr Opin Cell Biol 2000 12: 186–192
Camps M, Nichols A, Arkinstall S . Dual specificity phosphatases: a gene family for control of MAP kinase function FASEB J 2000 14: 6–16
Sun H, Charles CH, Lau LF, Tonks NK . MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo Cell 1993 75: 487–493
King AG, Ozanne BW, Smythe C, Ashworth A . Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54jnk Oncogene 1995 11: 2553–2563
Guan KL, Butch E . Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase J Biol Chem 1995 270: 7197–7203
Muda M, Theodosiou A, Rodrigues N, Boschert U, Camps M, Gillieron C, Davies K, Ashworth A, Arkinstall S . The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases J Biol Chem 1996 271: 27205–27208
Muda M, Boschert U, Dickinson R, Martinou JC, Martinou I, Camps M, Schlegel W, Arkinstall S . MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase J Biol Chem 1996 271: 4319–4326
Muda M, Boschert U, Smith A, Antonsson B, Gillieron C, Chabert C, Camps M, Martinou I, Ashworth A, Arkinstall S . Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4 J Biol Chem 1997 272: 5141–5151
Tanoue T, Moriguchi T, Nishida E . Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5 J Biol Chem 1999 274: 19949–19956
Theodosiou A, Smith A, Gillieron C, Arkinstall S, Ashworth A . MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases Oncogene 1999 18: 6981–6988
Tanoue T, Yamamoto T, Maeda R, Nishida E . A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs J Biol Chem 2001 276: 26629–26639
Marti F, Krause A, Post NH, Lyddane C, Dupont B, Sadelain M, King PD . Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6 J Immunol 2001 166: 197–206
Brondello JM, Brunet A, Pouyssegur J, McKenzie FR . The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade J Biol Chem 1997 272: 1368–1376
Shapiro PS, Ahn NG . Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1) J Biol Chem 1998 273: 1788–1793
Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, Boschert U, Arkinstall S . Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase Science 1998 280: 1262–1265
Reffas S, Schlegel W . Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells Biochem J 2000 352: 701–708
Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P, Hardie DG . Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism Nature 1989 337: 78–81
Orgad S, Brewis ND, Alphey L, Axton JM, Dudai Y, Cohen PT . The structure of protein phosphatase 2A is as highly conserved as that of protein phosphatase 1 FEBS Lett 1990 275: 44–48
Wassarman DA, Solomon NM, Chang HC, Karim FD, Therrien M, Rubin GM . Protein phosphatase 2A positively and negatively regulates Ras1-mediated photoreceptor development in Drosophila Genes Dev 1996 10: 272–278
Manfroid I, Martial JA, Muller M . Inhibition of protein phosphatase PP1 in GH3B6, but not in GH3 cells, activates the MEK/ERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPB/p300 Mol Endocrinol 2001 15: 625–637
Chung H, Brautigan DL . Protein phosphatase 2A suppresses MAP kinase signalling and ectopic protein expression Cell Signal 1999 11: 575–580
Braconi Quintaje SB, Church DJ, Rebsamen M, Valloton MB, Hemmings BA, Lang U . Role of protein phosphatase 2A in the regulation of mitogen-activated protein kinase activity in ventricular cardiomyocytes Biochem Biophys Res Commun 1996 221: 539–547
Jaumot M, Hancock JF . Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14–3-3 interactions Oncogene 2000 20: 3949–3958
Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, Baccarini M . Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation J Biol Chem 2000 275: 22300–22304
Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E . Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A Cell Growth Differ 1994 5: 995–1004
Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, Panayotou G, Ruiz-Larrea F, Thompson A, Totty NF et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit Cell 1992 70: 419–429
Klippel A, Escobedo JA, Fantl WJ, Williams LT . The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor Mol Cell Biol 1992 12: 1451–1459
Whitman M, Downes CP, Keeler M, Keller T, Cantley L . Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate Nature 1988 332: 644–646
Anderson KE, Coadwell J, Stephens LR, Hawkins PT . Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B Curr Biol 1998 8: 684–691
Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA . Mechanism of activation of protein kinase B by insulin and IGF-1 EMBO J 1996 15: 6541–6551
Alessi DR, Deak M, Casamayor A, Caudwell FB, Morrice N, Norman DG, Gaffney P, Reese CB, MacDougall CN, Harbison D, Ashworth A, Bownes M . 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase Curr Biol 1997 7: 776–789
Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK . The akt kinase: molecular determinants of oncogenicity Proc Natl Acad Sci USA 1998 95: 14950–14955
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P . Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha Curr Biol 1997 7: 261–269
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 1997 91: 231–241
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt Science 1997 278: 687–689
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC . Regulation of cell death protease caspase-9 by phosphorylation Science 1998 282: 1318–1321
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME . Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 1999 96: 857–868
Kane LP, Shapiro VS, Stokoe D, Weiss A . Induction of NF-kappaB by the Akt/PKB kinase Curr Biol 1999 9: 601–604
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 1997 275: 1943–1947
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 1998 95: 29–39
Gu J, Tamura M, Yamada KM . Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways J Cell Biol 1998 143: 1375–1383
Maehama T, Dixon JE . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J Biol Chem 1998 273: 13375–13378
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK . The lipid phosphatase activity of PTEN is critical for its tumor supressor function Proc Natl Acad Sci USA 1998 95: 13513–13518
Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP . Pten is essential for embryonic development and tumour suppression Nat Genet 1998 19: 348–355
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R . Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proc Natl Acad Sci USA 1999 96: 1563–1568
Arcaro A, Wymann MP . Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses Biochem J 1993 296: 297–301
Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, Vlahos CJ . Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase Cancer Res 1994 54: 2419–2423
Vlahos CJ, Matter WF, Hui KY, Brown RF . A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) J Biol Chem 1994 269: 5241–5248
Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP . 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth J Med Chem 2000 43: 3045–3051
King WG, Mattaliano MD, Chan TO, Tsichlis PN, Brugge JS . Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation Mol Cell Biol 1997 17: 4406–4418
Wennstrom S, Downward J . Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor Mol Cell Biol 1999 19: 4279–4288
Sheng H, Shao J, DuBois RN . Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells J Biol Chem 2001 276: 14498–14504
von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, Troppmair J . Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals Mol Cell Biol 2001 21: 2324–2236
McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC . Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells Cancer Detect Prev 2001 25: 375–393
Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K . Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells J Biol Chem 2001 276: 33630–33637
Guan KL, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD, Vojtek AB . Negative regulation of the serine/threonine kinase B-Raf by Akt J Biol Chem 2000 275: 27354–27359
Zimmermann S, Moelling K . Phosphorylation and regulation of Raf by Akt (protein kinase B) Science 1999 286: 1741–1744
Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, Glass DJ . Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt Science 1999 286: 1738–1741
Ruvolo PP, Deng X, May WS . Phosphorylation of Bcl2 and regulation of apoptosis Leukemia 2001 15: 515–522
Ruvolo PP . Ceramide regulates cellular homeostasis via diverse stress signaling pathways Leukemia 2001 15: 1153–1160
Acknowledgements
This work was supported in part by RO1CA51025 from the National Cancer Institute and 2000-ARG-0003 from the North Carolina Biotechnology Center. We wish to thank Ms Catherine Spruill for the excellent artwork.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee Jr, J., McCubrey, J. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16, 486–507 (2002). https://doi.org/10.1038/sj.leu.2402460
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402460
Keywords
This article is cited by
-
Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias
Leukemia (2023)
-
Eukaryotic initiation factor-2, gamma subunit, suppresses proliferation and regulates the cell cycle via the MAPK/ERK signaling pathway in acute myeloid leukemia
Journal of Cancer Research and Clinical Oncology (2021)
-
Sanguinarine inhibits the proliferation of BGC-823 gastric cancer cells via regulating miR-96-5p/miR-29c-3p and the MAPK/JNK signaling pathway
Journal of Natural Medicines (2019)
-
HNRNPA2B1 regulates the epithelial–mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway
Cancer Cell International (2017)
-
Novel cycloartane triterpenoid from Cimicifuga foetida (Sheng ma) induces mitochondrial apoptosis via inhibiting Raf/MEK/ERK pathway and Akt phosphorylation in human breast carcinoma MCF-7 cells
Chinese Medicine (2016)
